• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发病机制、感染预防与治疗。

Pathogenesis, Infection Prevention and Treatment.

作者信息

Miggiano Riccardo, Rizzi Menico, Ferraris Davide M

机构信息

Department of Pharmaceutical Sciences, University of Piemonte Orientale, Via Bovio 6, 28100 Novara, Italy.

出版信息

Pathogens. 2020 May 18;9(5):385. doi: 10.3390/pathogens9050385.

DOI:10.3390/pathogens9050385
PMID:32443469
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7281116/
Abstract

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB) and it represents a persistent public health threat for a number of complex biological and sociological reasons. According to the most recent Global Tuberculosis Report (2019) edited by the World Health Organization (WHO), TB is considered the ninth cause of death worldwide and the leading cause of mortality by a single infectious agent, with the highest rate of infections and death toll rate mostly concentrated in developing and low-income countries. We present here the editorial section to the Special Issue entitled "Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment" that includes 7 research articles and a review. The scientific contributions included in the Special Issue mainly focus on the characterization of MTB strains emerging in TB endemic countries as well as on multiple mechanisms adopted by the bacteria to resist and to adapt to antitubercular therapies.

摘要

结核病(TB)是由结核分枝杆菌(MTB)引起的一种传染病,由于多种复杂的生物学和社会学原因,它对公共卫生构成持续威胁。根据世界卫生组织(WHO)编辑的最新《全球结核病报告》(2019年),结核病被认为是全球第九大致死原因,也是单一感染源导致死亡的主要原因,感染率和死亡率最高的情况大多集中在发展中国家和低收入国家。在此,我们展示了题为“结核分枝杆菌的发病机制、感染预防与治疗”的特刊社论部分,该特刊包含7篇研究文章和1篇综述。该特刊中的科学贡献主要集中在结核病流行国家出现的MTB菌株的特征描述,以及细菌为抵抗和适应抗结核治疗所采用的多种机制。

相似文献

1
Pathogenesis, Infection Prevention and Treatment.发病机制、感染预防与治疗。
Pathogens. 2020 May 18;9(5):385. doi: 10.3390/pathogens9050385.
2
Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.社论:结核杆菌药物靶点的现状与展望以及基于构效关系的抗结核药物设计
Curr Pharm Des. 2014;20(27):4305-6. doi: 10.2174/1381612819666131118203915.
3
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发:现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
4
Tuberculosis结核病
5
[Recent progress in mycobacteriology].[分枝杆菌学的最新进展]
Kekkaku. 2007 Oct;82(10):783-99.
6
The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.表观遗传学、细菌和宿主因素在结核分枝杆菌感染进展中的作用。
Tuberculosis (Edinb). 2018 Dec;113:200-214. doi: 10.1016/j.tube.2018.10.009. Epub 2018 Oct 30.
7
[Frontier of mycobacterium research--host vs. mycobacterium].[分枝杆菌研究前沿——宿主与分枝杆菌]
Kekkaku. 2005 Sep;80(9):613-29.
8
Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.利用生物学洞察力加速结核病药物发现。
Acc Chem Res. 2019 Aug 20;52(8):2340-2348. doi: 10.1021/acs.accounts.9b00275. Epub 2019 Jul 30.
9
Recent updates on drug resistance in Mycobacterium tuberculosis.结核分枝杆菌耐药性的最新研究进展。
J Appl Microbiol. 2020 Jun;128(6):1547-1567. doi: 10.1111/jam.14478. Epub 2019 Oct 29.
10
[Prospects for development of new antituberculous drugs].[新型抗结核药物的发展前景]
Kekkaku. 2002 Aug;77(8):573-84.

引用本文的文献

1
Recent progress in tuberculosis diagnosis: insights into blood-based biomarkers and emerging technologies.结核病诊断的最新进展:对血液生物标志物和新兴技术的见解
Front Cell Infect Microbiol. 2025 May 8;15:1567592. doi: 10.3389/fcimb.2025.1567592. eCollection 2025.
2
Prevalence and predictors of unsuccessful tuberculosis treatment outcomes among persons with TB/HIV co-infection in Ghana: a 10-year retrospective study.加纳结核病/艾滋病病毒合并感染患者结核病治疗结果未成功的患病率及预测因素:一项10年回顾性研究
BMC Infect Dis. 2025 May 6;25(1):669. doi: 10.1186/s12879-025-11054-7.
3
Clinical characteristics and prognostic factors of pulmonary tuberculosis with interstitial changes.伴有间质改变的肺结核的临床特征及预后因素
BMC Infect Dis. 2025 Apr 29;25(1):624. doi: 10.1186/s12879-025-10970-y.
4
Development and validation of a nomogram for predicting pulmonary embolism in patients with pulmonary tuberculosis.用于预测肺结核患者肺栓塞的列线图的开发与验证
J Thorac Dis. 2025 Mar 31;17(3):1197-1206. doi: 10.21037/jtd-24-1627. Epub 2025 Mar 27.
5
Detection of Mycobacteria in Arabian camels and antimycobacterial potential of Moringa oleifera.阿拉伯骆驼体内分枝杆菌的检测及辣木的抗分枝杆菌潜力
Sci Rep. 2025 Apr 4;15(1):11590. doi: 10.1038/s41598-025-92402-0.
6
The relationship between ferroptosis and respiratory infectious diseases: a novel landscape for therapeutic approach.铁死亡与呼吸道感染性疾病之间的关系:治疗方法的新前景。
Front Immunol. 2025 Mar 18;16:1550968. doi: 10.3389/fimmu.2025.1550968. eCollection 2025.
7
Mycobacterium tuberculosis: The Mechanism of Pathogenicity, Immune Responses, and Diagnostic Challenges.结核分枝杆菌:致病性机制、免疫反应及诊断挑战
J Clin Lab Anal. 2024 Dec;38(23):e25122. doi: 10.1002/jcla.25122. Epub 2024 Nov 26.
8
Predictive value of systemic immune-inflammatory biomarkers for drug-induced liver injury in hepatitis B virus surface antigen positive tuberculosis patients: A retrospective observational study.系统免疫炎症生物标志物对乙肝表面抗原阳性结核病患者药物性肝损伤的预测价值:一项回顾性观察研究。
Medicine (Baltimore). 2024 Nov 8;103(45):e40349. doi: 10.1097/MD.0000000000040349.
9
Treatment and Toxicity Considerations in Tuberculosis: A Narrative Review.结核病的治疗与毒性考量:一篇叙述性综述
Cureus. 2024 Jun 19;16(6):e62698. doi: 10.7759/cureus.62698. eCollection 2024 Jun.
10
Asthmatic patients with vitamin D deficiency: Can vitamin D supplementation make a difference.哮喘患者维生素 D 缺乏:维生素 D 补充剂有作用吗?
Technol Health Care. 2024;32(6):3985-4008. doi: 10.3233/THC-231462.

本文引用的文献

1
Preclinical Evidence of Nanomedicine Formulation to Target at Its Bone Marrow Niche.纳米药物制剂靶向其骨髓生态位的临床前证据。
Pathogens. 2020 May 13;9(5):372. doi: 10.3390/pathogens9050372.
2
Genome Subtraction and Comparison for the Identification of Novel Drug Targets against subsp. .用于鉴定针对亚种的新型药物靶点的基因组扣除与比较
Pathogens. 2020 May 12;9(5):368. doi: 10.3390/pathogens9050368.
3
Genotyping, Assessment of Virulence and Antibacterial Resistance of the Rostov Strain of Attributed to the Central Asia Outbreak Clade.归因于中亚暴发分支的罗斯托夫菌株的基因分型、毒力评估及抗菌耐药性研究
Pathogens. 2020 Apr 30;9(5):335. doi: 10.3390/pathogens9050335.
4
Intelligent Mechanisms of Macrophage Apoptosis Subversion by .巨噬细胞凋亡颠覆的智能机制 作者:. (原文此处不完整)
Pathogens. 2020 Mar 16;9(3):218. doi: 10.3390/pathogens9030218.
5
Targeting Genome Integrity in : From Nucleotide Synthesis to DNA Replication and Repair.靶向基因组完整性:从核苷酸合成到 DNA 复制和修复。
Molecules. 2020 Mar 7;25(5):1205. doi: 10.3390/molecules25051205.
6
Immune Phenotype and Functionality of Specific T-Cells in HIV/TB Co-Infected Patients on Antiretroviral Treatment.接受抗逆转录病毒治疗的HIV/TB合并感染患者中特定T细胞的免疫表型和功能
Pathogens. 2020 Mar 2;9(3):180. doi: 10.3390/pathogens9030180.
7
MmpS5-MmpL5 Transporters Provide Resistance to imidazo[1,2-][1,2,4,5]tetrazines.MmpS5-MmpL5转运蛋白赋予对咪唑并[1,2 - ][1,2,4,5]四嗪的抗性。
Pathogens. 2020 Feb 28;9(3):166. doi: 10.3390/pathogens9030166.
8
Metabolic Changes of during the Anti-Tuberculosis Therapy.抗结核治疗期间的代谢变化 。 你提供的原文似乎不完整,“Metabolic Changes of ”后面缺少具体内容。
Pathogens. 2020 Feb 18;9(2):131. doi: 10.3390/pathogens9020131.
9
Detection of Second Line Drug Resistance among Drug Resistant Mycobacterium Tuberculosis Isolates in Botswana.博茨瓦纳耐药结核分枝杆菌分离株二线耐药性的检测
Pathogens. 2019 Oct 28;8(4):208. doi: 10.3390/pathogens8040208.
10
Building a tuberculosis-free world: The Lancet Commission on tuberculosis.打造无结核病世界:《柳叶刀》结核病委员会
Lancet. 2019 Mar 30;393(10178):1331-1384. doi: 10.1016/S0140-6736(19)30024-8. Epub 2019 Mar 20.